Post by PharmaShots

The US FDA accepts Pharvaris’ NDA for Deucrictibant IR, a potential first oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema attacks Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #pharvaris #usfda #nda #deucrictibantir #hereditaryangioedema #rapide3 #piii #smallmolecule #bradykininb2receptor #pdufa #regulatory #raredisease https://lnkd.in/dhxi6NmY